In a collaborative effort to combat the mpox outbreak, UNICEF, in partnership with Gavi, the Africa CDC, and the World Health Organization (WHO), has issued an emergency tender for mpox vaccines to ensure swift access to life-saving vaccines for countries hardest hit by the recent surge in cases.
The tender outlines the potential for agreements with vaccine manufacturers for up to 12 million doses through 2025, depending on production capacity.
UNICEF will utilize conditional supply agreements, allowing for immediate purchase and shipment of vaccines once financing, demand, readiness, and regulatory requirements are met.
WHO is currently reviewing information submitted by manufacturers regarding two vaccines – one produced by Bavarian Nordic and another by Japan's KM Biologics – for potential emergency use listing. A decision on emergency licenses is expected by mid-September.